Sites of Extranodal Involvement (369 Patients) and Kaplan Meier Estimate of Probability of CNS Recurrence at 1 Year After Diagnosis
| . | N (%) . | Probability of CNS Recurrence (95% CI) . | P* . |
|---|---|---|---|
| Bone marrow | |||
| Yes | 47 (12.7) | 18.5 (12.1-24.9) | .005 |
| No | 322 (87.3) | 5.2 (5.1-5.3) | |
| Bones | |||
| Yes | 36 (9.8) | 9.1 (5.1-13.1) | .61 |
| No | 333 (90.2) | 6.4 (6.3-6.5) | |
| Lungs/pleura | |||
| Yes | 29 (7.9) | 11.9 (5.5-18.3) | .116 |
| No | 340 (92.1) | 6.3 (6.2-6.4) | |
| GI tract | |||
| Yes | 39 (9.2) | 9.3 (4.2-14.4) | .347 |
| No | 330 (90.8) | 6.4 (6.3-6.5) | |
| Sinuses | |||
| Yes | 9 (2.4) | 12.5 (0.9-24.1) | .432 |
| No | 360 (97.6) | 6.6 (6.5-6.7) | |
| Liver/kidney/GU/adrenals/thyroid | |||
| Yes | 33 (8.9) | 19.0 (12.3-26.7) | .03 |
| No | 330 (91.1) | 5.7 (5.6-5.8) | |
| Skin/scalp/subcutaneous tissue/muscle | |||
| Yes | 23 (6.2) | 23.9 (14.5-33.3) | .002 |
| No | 346 (93.8) | 5.6 (5.5-5.7) |
| . | N (%) . | Probability of CNS Recurrence (95% CI) . | P* . |
|---|---|---|---|
| Bone marrow | |||
| Yes | 47 (12.7) | 18.5 (12.1-24.9) | .005 |
| No | 322 (87.3) | 5.2 (5.1-5.3) | |
| Bones | |||
| Yes | 36 (9.8) | 9.1 (5.1-13.1) | .61 |
| No | 333 (90.2) | 6.4 (6.3-6.5) | |
| Lungs/pleura | |||
| Yes | 29 (7.9) | 11.9 (5.5-18.3) | .116 |
| No | 340 (92.1) | 6.3 (6.2-6.4) | |
| GI tract | |||
| Yes | 39 (9.2) | 9.3 (4.2-14.4) | .347 |
| No | 330 (90.8) | 6.4 (6.3-6.5) | |
| Sinuses | |||
| Yes | 9 (2.4) | 12.5 (0.9-24.1) | .432 |
| No | 360 (97.6) | 6.6 (6.5-6.7) | |
| Liver/kidney/GU/adrenals/thyroid | |||
| Yes | 33 (8.9) | 19.0 (12.3-26.7) | .03 |
| No | 330 (91.1) | 5.7 (5.6-5.8) | |
| Skin/scalp/subcutaneous tissue/muscle | |||
| Yes | 23 (6.2) | 23.9 (14.5-33.3) | .002 |
| No | 346 (93.8) | 5.6 (5.5-5.7) |
*Fisher-Freeman-Halton exact test.